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Simposio
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Introduction
Passive case detection and treatment constitute 
the principal and often the sole measure of control 
for dermal leishmaniasis in Central and South 
America yet pentavalent antimonials, the first line 
therapy, are often ineffective. Treatment failure is 
frequent and concerning in the management of 
cutaneous leishmaniasis in South America. Overall 
non-response is of the order of 24% based on a 
recent metaanalysis (Tuon, et al., 2008). Although 
therapeutic response is multifactorial, treatment 
with Glucantime® has been shown to select 
antimony (Sbv)-tolerant/resistant parasites and 
drug resistance to contribute to treatment failure in 
some patients (Rojas, et al., 2006). 
Methods
In order to determine the susceptibility of the 
most prevalent Leishmania species affecting 
human populations in Colombia to currently 
used anti-leishmanial drugs, we evaluated 
in vitro susceptibility of 150 clinical strains of 
Leishmania braziliensis, Leishmania panamensis 
and Leishmania guyanensis from the major 
endemic regions of the country, to Glucantime® 
and miltefosine. Susceptibility was determined 
based on reduction of intracellular parasite burden 
in human U-937 macrophages by screening at 
single drug concentrations and ED50 determination. 
Experimentally selected antimony and miltefosine 
resistant lines and the corresponding wild type strains 
provided internal standards. Low susceptibility was 
defined as <50% reduction of parasite burden 
at the screening concentration of 32 µg Sbv/ml, 
based on the Cmax of antimony in plasma during 
treatment, and 16 µM for miltefosine considering 
the susceptibility profile of experimentally selected 
resistant lines and toxicity of higher concentrations 
for U-937 host cells. 
Results
Susceptibility to miltefosine and Glucantime® 
differed among species and by geographic origin. 
Between 20 to 50% of L. panamensis, and 40 to 53% 
of L. braziliensis strains presented low susceptibility 
for Sb, depending upon the geographic origin of 
the infection. Low susceptibility to miltefosine was 
evident in 14 to 80% of L. panamensis, and 58 to 
79% for L. braziliensis. In contrast, all L. guyanensis 
strains were highly susceptible to both antimony 
and miltefosine. Leishmania from the Orinoco and 
Amazon River basin regions were less sensitive to 
both drugs than strains from other high transmission 
areas. 
Leishmania braziliensis presented low sensitivity 
to both drugs more frequently than other species 
of the (Viannia) subgenus. No significant difference 
in susceptibility to Sb was detected among strain 
cohorts (N=85) isolated between 1980-1989 and 
2000-2009 in the municipality of Tumaco. However 
during the 1980-1989 period, a higher proportion of 
strains from the Rosario river focus presented low 
susceptibility to antimony than strains from the Mira 
river focus (50% vs. 27%, p=0.032). 
Discussion
The results of this large scale evaluation of 
clinical strains support both intrinsic and acquired 
differences in drug susceptibility of Leishmania 
(Viannia) species. Although L. braziliensis and 
L. panamensis strains frequently presented low 
susceptibility to antimony or miltefosine, many 
strains of both species were highly susceptible to 
one or both, demonstrating that the species are 
not intrinsically less susceptible to these drugs, 
rather individual strains may be intrinsically less 
susceptible. 
Because L. panamensis and L. braziliensis are 
the most prevalent species among human cases 
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of cutaneous leishmaniasis and infection is not 
eliminated by treatment (Schubach, et al., 1998; 
Vergel, et al., 2006), decades of monotherapeutic 
use of antimonial drugs is likely to have selected 
tolerant and even resistant populations of these 
species that could have been disseminated in 
circumstances of anthroponotic transmission. 
Leishmania guyanensis is of low prevalence, 
and until recently has been confined to sylvatic 
transmission in the Amazon river basin (Rodríguez-
Barraquer, et al., 2008). The uniform, high 
susceptibility of L. guyanensis strains to antimony 
concurs with limited exposure to large scale 
treatment with this drug. 
Miltefosine was approved as an alternative 
treatment by the Ministry of Social Protection in 
2006 and has had limited availability and use. 
Differences in susceptibility to miltefosine among 
species and strains are therefore likely to reflect 
intrinsic variability rather than acquired loss of 
susceptibility.
Conclusion
The high frequency of clinical strains of Leishmania 
with evidence of low susceptibility to antimonial drugs 
or miltefosine underscores the risk of treatment 
failure and the need to develop alternative therapies 
including combined and local treatments. 
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É possível o desenvolvimento de novos medicamentos para 
as doenças negligenciadas?
Isabela Ribeiro, Mariana Abdalla, Eric Stobbaerts
Drugs for Neglected Diseases initiative, Rio de Janeiro, Brasil
• • •  
Segundo a Organização Mundial da Saúde, as 
doenças negligenciadas afetam mais de um bilhão 
de pessoas no mundo, principalmente em áreas 
rurais, periferias metropolitanas pobres e zonas de 
conflito, contribuindo para a manutenção do ciclo 
da pobreza. Por atingirem populações com pouca 
visibilidade, pouca representatividade política e, 
principalmente pouco ou nenhum poder de compra, 
esses números não se traduzem em investimentos 
adequados em pesquisa e desenvolvimento. Por 
isto, os desequilíbrios resultantes exigem respostas 
alternativas do mundo da ciência, mercado e 
sistemas públicos de saúde para atenderem às 
demandas mais urgentes de saúde global.
Nos últimos anos houve uma tendência em nível 
mundial de buscar alternativas para esta situação 
com modelos de colaboração e articulação entre 
diversos setores, explicitada por Carlos M. Morel 
e Richard T. Mahoney no artigo “A Global Health 
Innovation System (GHIS)” como a “era das 
parcerias”. Entre os modelos de parcerias existentes 
se encontram as parcerias para desenvolvimento 
de produtos. As parcerias para desenvolvimento 
de produtos concentram-se em uma ou mais 
doença negligenciada e visam o desenvolvimento 
de produtos apropriados para estas. Apesar de 
constituírem um modelo relativamente recente, 
o número de parcerias para desenvolvimento de 
produtos tem aumentado desde o final da década 
de 90. Com um modelo virtual de organização, 
estas trabalham com expertos, e providenciam 
financiamento, supervisão técnica e a gestão do 
portfólio, enquanto as atividades são delegadas 
a parceiros de diversos setores (Cheri, p. 7). As 
parcerias para desenvolvimento de produtos 
conseguem abranger múltiplos parceiros no setor 
privado, público, acadêmico e filantrópico, assim 
como, muitas vezes, conduzir ações de advocacy 
de maneira a conscientizar diferentes públicos 
acerca das doenças negligenciadas em alvo 
(Moran, et al., p. 68).
Ao canalizarem suas diversas contribuições, e 
providenciarem investimentos diretos em pesquisas, 
as parcerias para desenvolvimento de produtos 
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com freqüência têm custos de operações mais 
baixos, assim como alto grau de efetividade. Em 
recente pesquisa financiada por Wellcome Trust, 
foi demonstrada as vantagens comparativas das 
parcerias público-privadas para desenvolvimento 
de produtos. Além de terem alcançado resultados 
positivos, tais como a disponibilização de 10 
novas tecnologias e a existência de 143 novos 
candidatos no seu “pipeline” de desenvolvimento, 
as parcerias para desenvolvimento de produtos 
ainda se mostram mais eficazes em termos de 
tempo de desenvolvimento, custo-eficiência, valor 
para a saúde e níveis de inovação dos produtos. 
Em termos de vantagens externas, as parcerias 
para desenvolvimento de produtos se destacaram 
pelo seu conhecimento profundo de mercado 
e necessidades, seu envolvimento público 
significativo no local de trabalho, sua capacidade 
de definição de parâmetros regulatórios, de 
desenvolvimento de estratégias sustentáveis de 
distribuição e acesso, e de aumento da visibilidade 
das doenças negligenciadas.
A Iniciativa Medicamentos para Doenças 
Negligenciadas (Drugs for Neglected Diseases 
initiative, DNDi) é uma das pioneiras entre as 
parcerias para desenvolvimento de produtos. 
Desde sua criação em 2003, a DNDi concentrou-
se principalmente no desenvolvimento de 
novos tratamentos para doenças extremamente 
negligenciadas, tais como a doença do sono, a 
leishmaniose visceral e a doença de Chagas. 
O principal objetivo da DNDi é fornecer até 2014 
de 6 a 8 novos tratamentos para a leishmaniose, a 
doença do sono, a doença de Chagas e a malária, e 
também estabelecer um portfólio sólido de projetos 
de pesquisa e desenvolvimento para desenvolver 
tratamentos que atendam as necessidades dos 
pacientes. Houve estabelecimento de estratégia 
e objetivos de curto, médio e longo prazo, com 
priorização de acordo com sua possibilidade de 
disponibilização e necessidades existentes. 
Grandes avanços foram alcançados desde sua 
criação com disponibilização de duas combinações 
em dose-fixa para malária falciparum; uma nova 
combinação de nifurtimox e eflornitina para 
o tratamento de primeira linha da doença do 
sono, assim como uma nova combinação para 
leishmaniose visceral. No campo da doença de 
Chagas, a DNDi em colaboração com o laboratório 
LAFEPE, submeteu para registro uma nova 
apresentação pediátrica para o benznidazol. O 
estudo clínico de farmacocinética populacional 
foi iniciado em vários centros na Argentina, tendo 
como investigador principal a Jaime Altcheh. 
Também como projeto em fase de desenvolvimento 
clínico em parceria com a empresa Eisai, avalia-se 
a segurança e eficácia do E1224, uma pró-droga 
do ravuconazol, para o tratamento dos pacientes 
na fase crônica indeterminada da doença. 
Um projeto em colaboração com Médicos Sem 
Fronteiras avalia novas técnicas para otimização de 
procedimentos da PCR em tempo real, em especial 
o número e volume de amostras necessárias para 
aumento de sensibilidade. Em fase pré-clínica, 
implementase a triagem de compostos de alto 
rendimento (High-Throughput Screening). Em 
colaboração com o Instituto Pasteur-Coréia, DNDi 
desenvolveu tecnologia para triagem de compostos 
em escala, permitindo a avaliação exploratória de 
grandes bibliotecas de compostos. Por último, 
temos ainda as atividades do Consórcio para a 
Otimização de Compostos Líderes. Este projeto 
iniciado em 2008, em parceria com o Centro 
de Otimização de Candidatos a Medicamentos 
(Centre for Drug Candidate Optimisation, CDCO), 
Epichem, a Universidade de Murdoch na Austrália 
e a Universidade Federal de Ouro Preto, no Brasil, 
tem hoje algumas moléculas e classes promissoras 
identificadas. 
Certamente é importante lembrar as necessi-
dades de políticas de incentivo à pesquisa e 
desenvolvimento em medicamentos para doenças 
negligenciadas que venham a viabilizar a 
sustentabilidade de iniciativas, assim como 
resolver os desafios e hiatos burocráticos e 
restritivos à inovação. No entanto, o progresso 
destes últimos anos nos aponta para um futuro 
de contínua articulação em prol de parcerias e de 
melhor resposta às necessidades das populações 
negligenciadas.
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Development of new drugs for visceral leishmaniasis
Philipe Desjeux
OneWorld Health, San Francisco, CA, USA
• • •  
During the last 15 years, several new drugs have 
been made available for the treatment of visceral 
leishmaniasis, most of them through highly relevant 
public-private partnerships. One of the first efforts 
was the validation of a cheap generic pentavalent 
antimonial, called sodium antimony gluconate 
and produced in India. However, appearance of 
resistance quickly limited its use in India. 
The traditional amphotericin B deoxycholate 
(Fungizone®), in use for more than 50 years, 
remains a highly effective drug with an efficacy rate 
of at least 97%. Its main limitations are: the need for 
a close monitoring of the prolonged infusions, the 
frequent, although controllable, adverse events and 
the relatively high cost. However, the acceptability 
of amphotericin B remains high. 
Miltefosine, developed through a partnership 
between Zentaris/Aeterna and WHO/TDR, is the 
first oral drug for visceral leishmaniasis. It is an 
alkyl phospholipid analogue, initially used as anti-
neoplastic drug. It has been adopted by India, Nepal 
and Bangladesh as the first-line drug for the visceral 
leishmaniasis elimination program. However, it 
is contraindicated in pregnant women, and child-
bearing age women have to use contraception up 
to two months after the end of treatment due to the 
potential risk of teratogenicity of the drug and its 
long half-life. DOT-like surveillance system has to 
be urgently put in place as lack of compliance is 
common and risk of resistance is increasing.
Although antileishmanial activity of intramuscular 
paromomycin was discovered in the 1960’s, its 
development has been slow. Fortunately, with 
commitment to support the visceral leishmaniasis
elimination program in India, Nepal and Bangladesh, 
OneWorld Health, together with WHO/TDR, secured 
a grant from the BMGF, to carry out phase III and 
IV clinical trials in Bihar State of India. Following 
its development, intramuscular paromomycin is 
now included among the WHO essential drug list 
and has been granted the status of orphan drug 
by EMEA and the Food and Drug Administration. 
Intramuscular paromomycin is safe, effective, and 
affordable. It has also been registered with the Drug 
Controller General of India in 2006. Main limitations 
are the duration of treatment (21 days) and injection 
site pain, the most frequent adverse event.
Among the lipid formulations of amphotericin B, 
Ambisome® (a liposomal formulation from Gilead) 
is the most extensively used and several regimens 
have been tested successfully. The drug has a high 
safety profile. Side-effects are limited. So far, no 
resistance has been reported. Even a single dose 
of Ambisome® has proved to be highly effective (5 
mg/kg: 91% cure, 10 mg/kg: 96% cure). WHO has 
been able to negotiate a preferential price of US$ 
20 per vial of 50 mg, making Ambisome® more 
accessible for visceral leishmaniasis patients living 
in endemic countries. 
As there is no new compound expected to be 
developed in the next 5 years, any effort should be 
made to preserve the efficacy of currently available 
drugs. There is an urgent need to set up pharmaco-
vigilance and drug-resistance surveillance systems. 
Indiscriminate use by inexperienced health care 
providers should be prevented. 
Another option is to promote the use of combo 
therapies and evaluate their respective efficacy, 
safety and practicality in different regions. In India, 
an evaluation of the different options for combo 
therapy has been recently achieved by Drug for 
Neglected Diseases Initiative (DNDi). It has shown 
that the 3 main options (Ambisome® + miltefosine, 
Ambisome® + intramuscular paromomycin and 
intramuscular paromomycin + miltefosine) have, in 
India, a similar high efficacy (98%) and all were well 
tolerated.
A consortium project, which includes three 
partners: the Drug for Neglected Diseases Initiative 
(DNDi), OneWorld Health and WHO/TDR, has just 
started. Its goal is to evaluate the feasibility to use a 
single-dose Ambisome® in combination with either 
intramuscular paromomycin or miltefosine, and the 
use of intramuscular paromomycin plus miltefosine 
at the district hospital and primary health care levels. 
The rationale to use combo therapies is to reduce 
the duration of treatment, improve the compliance, 
reduce the risk of resistance, reduce the cost and 
enhance efficacy. 
In South-Asia, the main goal of all these studies 
is to contribute to the visceral leishmaniasis 
elimination program by reducing the burden of the 
disease in endemic rural communities of India, 
Bangladesh, and Nepal in coordination with the 
partners and respective governments. In East 
Africa other combo therapies are currently under 
evaluation. In South America, studies on combo 
therapies are already planned to start soon.
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Two clinical entities: post kala-azar dermal 
leishmaniasis, a cutaneous complication of visceral 
leishmaniasis, and the leishmania/HIV coinfection 
entity which is becoming more frequent, deserve 
more attention. Current treatments are long and 
toxic. New schemes of treatment have to be 
evaluated urgently.
Any new drug has to be, not only safe and efficient, 
but also available, accessible and affordable. 
Visceral leishmaniasis remains a highly neglected 
disease, but the recent availability of new tools for 
control makes it more promising.
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Program update on a topical paromomycin plus gentamicin formulation 
(WR279,396) for the treatment of cutaneous leishmaniasis
Max Grogl1, Afif Ben Salah2, Pierre Buffet3, Mara Kreishman-Deitrick4
 1  Walter Reed Army Institute of Research, Silver Spring, MD, USA
 2  nstitut Pasteur, Tunis, Tunisia
 3  Pr. Mazier Hôpital Pitie Salpetrière, Paris, France
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Global incidence of symptomatic leishmaniasis 
(all forms combined) is estimated at 2 million cases 
per year. Annual mortality is approximately 70,000. 
Disease burden is 2.4 million disability-adjusted life 
years (DALY). 
Of the 2 million patients suffering from 
leishmaniasis each year, approximately 1.0-1.5 
million have cutaneous leishmaniasis. Cutaneous 
leishmaniasis is among the most neglected of 
neglected diseases due to the fact that it affects 
the poorest of the poor and does not result in 
death. However, the true socioeconomic impact 
of cutaneous leishmaniasis cannot be quantified. 
Severe disfigurement, disability, and social/
psychological stigma often result. Cutaneous 
leishmaniasis is primarily an endemic disease, with 
epidemic outbreaks happening in both sedentary 
and mobile (military personnel, refugees, travelers) 
populations. Prevention is limited to personal 
protective measures such as insect repellent, bed 
nets, portable tent air conditioners, and control 
of disease reservoirs such as rodents and dogs. 
There are no vaccines or chemoprophylactic drugs 
to prevent leishmaniasis and there are no drugs 
approved by the Food and Drug Administration 
(FDA) for treatment of  cutaneous leishmaniasis. 
Cutaneous leishmaniasis has a significant impact 
on military populations serving in Iraq, Afghanistan, 
and other endemic areas. It is a chronic, disfiguring 
disease without a simple, safe, and widely 
effective treatment. Topical therapy of cutaneous 
leishmaniasis is both practical and desirable, yet 
such a product has not yet been developed for 
worldwide use. 
The aminoglycoside paromomycin is the most 
studied compound for topical treatment of cutaneous 
leishmaniasis, but testing of different formulations 
worldwide has led to mixed results. WR279,396 is 
a third generation topical antileishmanial cream, 
which contains 15% paromomycin and 0.5% 
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gentamicin. WR279,396 was formulated in a 
hydrophilic base that facilitates penetration and 
delivery of the active ingredients to sites containing 
Leishmania amastigotes. 
In a Balb/c mouse cutaneous leishmaniasis model, 
WR 279,396 cured lesions caused by multiple 
Leishmania strains in 100% of the mice without 
subsequent relapse. Significant progress has been 
made in the development program for WR279,396 
in the last 4 years. WR279,396 was scaled-up and 
manufactured by TEVA Pharmaceuticals USA, and 
has received orphan drug designation by the US 
FDA.
In the first phase 2, randomized, double blinded, 
placebo-controlled, multicenter study of Old World 
cutaneous leishmaniasis, 47 of the 50 (94%) 
subjects treated twice daily for 20 days with 
WR279,396 met the definition of complete clinical 
response, compared with 30 of the 42 vehicle 
subjects (71%). 
In a second phase 2 study in which WR 279,396 
was administered once-a-day for 20 days, the 
complete clinical response rate was 91.7% in the 
gauze-and-tape group. Additionally, at day 10, there 
was a statistically significant reduction in the parasite 
load in both the superficial dermis (52.8-fold) and 
the deep dermis (76.8-fold). WR279,396 was found 
to have a favorable safety profile with no deaths 
or serious adverse effects. All adverse effects were 
rated as mild to moderate in severity. There was no 
laboratory evidence of renal toxicity, no reports of 
vertigo, and no abnormal Romberg test results or 
audiometric evidence of clinical decreased hearing 
in patients who received WR279,396. 
Currently, a phase 3 pivotal clinical trial is 
underway in Tunisia, a second phase 3 trial is 
planned for the New World, and phase 2 studies 
are ongoing or planned in Washington, D.C., Peru, 
Panama, France, and Guatemala. The WR279,396 
development strategy, FDA approved clinical plan, 
and clinical results will be discussed. 
In summary, treatment optimization and final 
therapeutic decision in cutaneous leishmaniasis 
can be more complex than in visceral leishmaniasis, 
despite the greater severity of the later. Paradoxically, 
drugs used to treat visceral leishmaniasis are not 
necessarily efficacious in cutaneous leishmaniasis. 
The therapeutic decision is complicated by the 
numerous forms of the disease and the lack of a 
single drug that is efficacious against all of them. 
The efficacy of a new third generation 
paromomycin cream has been demonstrated in 
phase 2 studies, and further phase 2 and phase 
3 studies are ongoing. Additionally, current 
development efforts at the Walter Reed Army 
Institute of Research (WRAIR) are concentrated 
on finding a safe, oral drug that is effective against 
all forms of cutaneous leishmaniasis, has superior 
cosmetic results, and is affordable and adaptable 
for use in rural areas.
• • •  
Current business models to address research and development 
for products for neglected diseases 
Implications for developing countries: the good, the bad and the ugly
Janis Lazdins-Helds
Independent researcher, Geneva, Switzerland
The 1990 Commission on Health Research for 
Development made the first estimates of worldwide 
spending on health research and development (US$ 
30 billion) and in analysing the flows of resources 
described what became known as the “10/90 gap” 
– capturing the inequality revealed in their estimate 
that less than 10% of the global budget for health 
research and development was being spent on 
90% of the world’s health problems. 
To address the 10/90 gap different initiatives 
to enhance product research and development 
for neglected health problems were established. 
These initiatives are based on business models that 
promote partnerships and collaborations between 
the private and the public sector, with financing to a 
large extent from the philanthropic and international 
cooperation initiatives. Today the preponderant 
model is the so called product development 
partnerships that are non-for profit organizations 
with mandates to research, develop and support 
accessibility of new health technologies that target 
diseases disproportionately affecting developing 
countries. 
Product development partnerships typically 
employ a portfolio approach to research and 
development to accelerate product development 
working in close partnership with academia, large 
pharmaceutical companies, the biotechnology 
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• • •  
industry and governments in developed and 
developing countries. Product development part-
nerships typically use private industry approaches 
to portfolio and project management choosing and 
funding partners that offer the highest possibilities 
for successful outcomes. 
On the other hand, the pharmaceutical sector 
(private or public) has also responded to the “10/90 
gap” by establishing fully funded and dedicated 
facilities to address research and development 
for neglected tropical diseases. While recognizing 
the impact of the above initiatives, the World 
Health Organization (WHO) member states after a 
thorough and lengthy process agreed in 2008 on 
a World Health Assembly resolution (WHA 62.16. 
Global Strategy and Plan of Action on Public Health, 
Innovation and Intellectual Property) calling for:
i) strengthening the innovative capacity of 
developing countries, to support local 
researchers in driving research efforts required 
to respond to the local public health needs, 
and 
ii) promoting research aimed at ethically 
developing health products that are available 
in sufficient quantities, are effective, safe and 
of good quality, are affordable and accessible, 
and are used in a rational way. 
As a follow-up of this resolution an action plan 
and budget proposal was developed by the WHO 
and endorsed by the World Health Assembly. 
It is anticipated that this will lead to a significant 
scale-up of resources for research in developing 
countries. The key question that still remains to 
be answered is how to best use these political 
instruments and the available global resources to 
on one hand sustain the current initiatives (e.g., 
product development partnerships) and on the 
other to address the need of many developing 
countries to develop and strengthen local research 
and development initiatives that respond to local 
health priorities (even if those may not stand high 
among the global health agenda) while contributing 
to their socioeconomic development. 
The presentation will attempt to examine the 
existing global neglected tropical diseases product 
research and development models and frameworks 
and particularly address how they interface with 
institutions/organizations in developing countries 
highlighting issues, gaps and opportunities.
